Durect Corp (DRRX) Stock Price, Quote & News

Latest News on DRRX

Mar 26, 2025, 8:04 PM EDT - 8 days ago

DURECT Corporation (DRRX) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 4:05 PM EDT - 8 days ago

DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 19, 2025, 4:30 PM EDT - 15 days ago

DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

Feb 4, 2025, 7:30 AM EST - 2 months ago

DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 28, 2025, 10:09 AM EST - 2 months ago

DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence

Nov 25, 2024, 6:00 AM EST - 4 months ago

DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million

Nov 13, 2024, 10:17 PM EST - 5 months ago

DURECT Corporation (DRRX) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 4:01 PM EST - 5 months ago

DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 4:45 PM EST - 5 months ago

DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update

Oct 17, 2024, 8:30 AM EDT - 6 months ago

DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024

Sep 25, 2024, 8:00 AM EDT - 6 months ago

DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis

Sep 4, 2024, 4:30 PM EDT - 7 months ago

DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

Aug 13, 2024, 8:42 PM EDT - 8 months ago

DURECT Corporation (DRRX) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 4:01 PM EDT - 8 months ago

DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update

Aug 7, 2024, 4:30 PM EDT - 8 months ago

DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update

May 21, 2024, 8:00 AM EDT - 11 months ago

DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis

May 13, 2024, 9:54 PM EDT - 11 months ago

DURECT Corporation (DRRX) Q1 2024 Earnings Call Transcript

May 13, 2024, 4:05 PM EDT - 11 months ago

DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update

May 7, 2024, 4:30 PM EDT - 11 months ago

DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update

Apr 30, 2024, 7:00 AM EDT - 1 year ago

DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis

Mar 27, 2024, 6:07 PM EDT - 1 year ago

DURECT Corporation (DRRX) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 4:01 PM EDT - 1 year ago

DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 20, 2024, 4:30 PM EDT - 1 year ago

DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Mar 4, 2024, 7:00 AM EST - 1 year ago

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada

Feb 7, 2024, 6:48 PM EST - 1 year ago

DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Dec 18, 2023, 7:39 AM EST - 1 year ago

Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)

Nov 13, 2023, 6:50 PM EST - 1 year ago

DURECT Corporation (DRRX) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 4:05 PM EST - 1 year ago

DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update

Nov 9, 2023, 4:30 PM EST - 1 year ago

DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update

Nov 7, 2023, 4:01 PM EST - 1 year ago

DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality

Sep 7, 2023, 7:00 AM EDT - 1 year ago

DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

Aug 31, 2023, 4:30 PM EDT - 1 year ago

DURECT Corporation Announces Presentations in Upcoming Investor Conferences

Aug 9, 2023, 8:22 PM EDT - 1 year ago

DURECT Corporation (DRRX) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 4:05 PM EDT - 1 year ago

DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update

Aug 3, 2023, 4:30 PM EDT - 1 year ago

DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update

Jul 20, 2023, 8:00 AM EDT - 1 year ago

DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jun 7, 2023, 6:00 AM EDT - 1 year ago

DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

May 8, 2023, 10:42 PM EDT - 2 years ago

DURECT Corporation (DRRX) Q1 2023 Earnings Call Transcript

May 8, 2023, 4:05 PM EDT - 2 years ago

DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update

May 1, 2023, 7:03 PM EDT - 2 years ago

DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8

Apr 27, 2023, 5:11 PM EDT - 2 years ago

DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis

Apr 25, 2023, 6:45 PM EDT - 2 years ago

DURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference

Apr 10, 2023, 6:00 AM EDT - 2 years ago

DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis

Mar 21, 2023, 4:30 PM EDT - 2 years ago

DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board

Mar 9, 2023, 8:30 AM EST - 2 years ago

DURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference

Mar 7, 2023, 6:46 PM EST - 2 years ago

DURECT Corp (DRRX) Q4 2022 Earnings Call Transcript

Mar 7, 2023, 4:05 PM EST - 2 years ago

DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update

Feb 28, 2023, 6:07 PM EST - 2 years ago

DURECT Corporation to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7

Feb 3, 2023, 5:17 PM EST - 2 years ago

DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants

Nov 28, 2022, 6:46 PM EST - 2 years ago

Market Cap	24.90M
Revenue (ttm)	2.03M
Net Income (ttm)	-8.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-409.85%
Debt to Equity Ratio	8.58

Volume	9,000
Avg Vol	46,044
Day's Range	N/A - N/A
Shares Out	31.04M
Stochastic %K	26%
Beta	0.88
Analysts	Strong Sell
Price Target	$6.75